by GOAI

由GOAI生成

Share To

分享到

Akums Drugs & Pharmaceuticals has introduced a new extended-release formulation of Gabapentin in India, designed for the management of postherpetic neuralgia. The Drug Controller General of India (DCGI) has approved this once-daily dosing medication, which aims to provide an alternative treatment option for individuals suffering from the chronic nerve pain condition..

阿库姆斯药物与制药公司在印度推出了一种新的加巴喷丁缓释制剂，用于治疗带状疱疹后神经痛。印度药物控制器总局（DCGI）已批准这种每日一次的剂量药物，旨在为遭受慢性神经痛的患者提供替代治疗选择。

The newly launched Gabapentin ER offers an extended-release mechanism, allowing patients to take the medication just once a day. This development is expected to simplify dosing regimens and potentially improve adherence among patients managing postherpetic neuralgia, a condition that often arises as a complication of shingles.

新推出的加巴喷丁缓释剂具有延长释放的机制，患者每天只需服用一次。这一进展有望简化给药方案，并可能提高管理带状疱疹后神经痛（一种常作为带状疱疹并发症出现的情况）患者的依从性。

The approval by DCGI marks its availability in the Indian pharmaceutical market, where it will be accessible to healthcare providers and patients seeking treatment options for this specific type of neuropathic pain..

DCGI的批准标志着它将在印度制药市场上市，医疗保健提供者和寻求治疗这种特定类型神经性疼痛的患者将可以获取该药物。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

For any suggestion and feedback, please contact us.

如有任何建议和反馈，请联系我们。

Date: December 15, 2025

日期：2025年12月15日

Related posts:

相关文章：

The key role of GMP analytical testing for drug products

药品GMP分析测试的关键作用

Galt Pharmaceuticals Announces Pharmaceutical Sales Role in Elmhurst Territory Under Franchise Model

高尔特制药公司宣布在埃尔姆赫斯特地区按照特许经营模式开展药品销售业务

Windows 7 Market Share Rises Tenfold as Windows 10 Support Nears End

随着 Windows 10 支持即将结束，Windows 7 市场份额增长了十倍

Sex-Specific Machine Learning Models Enhance Prediction Accuracy for Abdominal Aortic Aneurysms

性别特异性机器学习模型提高腹主动脉瘤预测准确性

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

电子邮件地址

Author

作者

GOAI

GOAI

Related Post

相关文章

News Flash

新闻快讯

FDA Approves Amgen’s Uplizna as First CD19-Targeted Therapy for Generalized Myasthenia Gravis with Twice-Yearly Dosing

FDA批准安进公司的Uplizna作为首个针对CD19的全身型重症肌无力疗法，每半年给药一次。

2025-12-15

2025年12月15日